Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216180 | 0.89 | KRAS (0.54) | KRASSMN1; SMN2ADRA2ACLCN2TAAR1 | |
| SCHEMBL3639756 | 0.88 | KRAS (0.54) | KRASSMN1; SMN2ADRA2ACLCN2TAAR1 | |
| Hydrochloric Acid SCHEMBL3614572 | 0.87 | KRAS (0.53) | KRASSMN1; SMN2ADRA2ACLCN2TAAR1 | |
| SCHEMBL3638377 | 0.87 | KRAS (0.51) | KRASSMN1; SMN2TAAR1MEN1KMT2A | |
| SCHEMBL3226447 | 0.86 | KRAS (0.51) | KRASSMN1; SMN2ADRA2ACLCN2TAAR1 | |
| SCHEMBL3234433 | 0.80 | KRAS (0.52) | KRASSMN1; SMN2TAAR1HTR1DHTR6 | |
| SCHEMBL3235519 | 0.78 | KRAS (0.45) | KRASSMN1; SMN2ADRA2ACLCN2TAAR1 | |
| SCHEMBL3235020 | 0.77 | SMN1; SMN2 (0.51) | KRASSMN1; SMN2ADRA2ATAAR1MEN1 | |
| Hydrochloric Acid SCHEMBL3582811 | 0.76 | SMN1; SMN2 (0.47) | KRASSMN1; SMN2ADRA2ACLCN2TAAR1 | |
| SCHEMBL3638115 | 0.75 | KRAS (0.43) | KRASSMN1; SMN2TAAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010012397-A1 | N-(INDOL-3-YLALKYL)(HETERO)ARYLAMIDE DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | PTGER2, PTGER1, PTGDR2 | KRAS 4229/4885SMN1; SMN2 1905/4885ADRA2A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.